The ACP plays a role in delivering various APIs (Active Pharmaceutical Ingredients) into targeted cells and tissues.

• The need for
  the development of CPP

• Even if a drug is developed, there should be a method to deliver it to the human body, which is called the DDS (Drug Delivery System). And, there are many types of DDS. Furthermore, there are diseases that can be treated only when APIs (active pharmaceutical ingredients) are delivered into cells. However, some of these APIs have larger size, so they cannot effectively pass through cell membranes, and there is no appropriate delivery method yet, so even if APIs are developed, they are often not developed into the actual drug..

• 
• Limitations of existing CPP

  The CPP (Cell Penetrating Peptide), a delivery system of APIs combined with cell-penetrating peptides, has been developed since the 1990s. However, there is an urgent need of the pharmaceutical industry because cell-penetrating substances that can be put to some practical use have still not been developed even though many potential substances have emerged.

• Excellence of the ACP

• The ACP (Advanced Cell-Penetrating Peptide), a CPP developed by Avixgen, has the following characteristics and advantages.